Lannion,
Revenues for the first nine months of 2020
Consolidated revenues (unaudited)
Chiffre d’affaires (M€) | 2020 | 2019 | reported change | organic change 1 | pro forma 2020 2 |
First quarter | 21.9 | 24.2 | -9.5% | -16.7% | |
Second quarter | 23.9 | 27.5 | -13.3% | -17.2% | |
Third quarter | 32.7 | 24.8 | +32.1% | -9.9% | |
First 9 months | 78.5 | 76.5 | +2.6% | -14.9% | 98.2 |
of which | |||||
Laser | 44.4 | 49.9 | -11.0% | -16.8% | 44.4 |
Médical | 34.1 | 26.6 | +28.3% | -11.5% | 53.8 |
1 Organic change: at constant exchange rates and like-for-like
2 Including Ellex at
The LUMIBIRD Group’s consolidated revenues came to €78.5m at
The third quarter was marked primarily by Ellex’s inclusion in the scope and a relatively stable historical level of Medical activity. The Laser division continued to be affected by the execution schedule, which was brought forward, on the Defense / Space contracts, as well as by the deferral of deliveries linked to the health crisis. The contraction in Q3 business on an organic basis to -9.9% was less marked than during the first half of the year (‑17.4%) and reflects the start of an upturn which is expected to continue in the fourth quarter.
For the Laser division, the Defense / Space business (-24.3% to €12.8m) is reporting significant progress with non-contract sales since the second quarter, partly offsetting the expected contraction on its longstanding contracts, with the new contracts still in their startup phase. The Industrial and Scientific business is virtually stable at end-September (-2.9% to €17.8m), thanks to third-quarter growth for OEM activities (flat screens and medical applications). The Lidar business is down (-6.0% to €13.8m), with contrasting results on the different business lines. The decline is mainly due to sales of LIDAR for autonomous vehicles where the Group is actively developing the new generation for Tier 4 and Tier 5 vehicles after a product delivery phase in 2019. In Parallel,
The Medical division (+28.3% to €34.1m) benefited from the inclusion in the scope of Ellex and Essmad in 2020 and Optotek Medical in 2019. The division recorded +105.8% third-quarter growth, with revenues of €18.3m. Ellex’s contribution came to €8.8m, with ESSMED contributing €0.4m and Pototek €0.4m. The balance of €8.7m shows relatively stable revenues compared with last year and reflects the positive trend for business on the historical scope, which was significantly affected by the crisis during the first half of the year, following the cancellation of major international ophthalmology conferences.
The effective management of the crisis, the commercial development actions rolled out and the rapid integration of Ellex are expected to deliver benefits and enable
The signs of recovery in the third quarter confirm the resilience and strong growth potential of the strategic markets that
Next dates:
2020 full-year revenues on
Born from the combination of
Contacts
Chairman and CEO Tel. +33(0) 1 69 29 17 00 info@lumibird.com | Aude Nomblot-Gourhand Secretary General – CFO Tel. +33(0) 1 69 29 17 00 info@lumibird.com | Calyptus Investors Relations Tel. +33(1) 53 65 37 91 lumibird@calyptus.net |
Attachment
- 201026LumibirdCAT32020EN
© OMX, source